Ireland
--:--IST
Recruiting Phase 4

Long-term Beta-blocker Therapy After Acute Myocardial Infarction

NCT04769362 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 4
Started
2021-05-04
Last updated
2025-12-29

Condition(s) studied

Myocardial Infarction

Investigational drug(s) / intervention(s)

Discontinuation of β-blocker

Discontinuation of β-blocker: Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction

Study summary

The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI).

Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject must be at least 19 years of age. * Subject who have been continuing β-blocker therapy for at least 1 year after acute myocardial infarction regardless of the time of diagnosis * Subject is able to verbally confirm understandings of risks and benefits of this trial, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: * Subject whose left ventricle ejection fraction was less than 40% from echocardiography performed after acute myocardial infarction or who have never received echocardiography. * Treatment history of heart failure * Contraindication to β-blocker therapy (history of symptomatic bronchial asthma or chronic obstructive pulmonary disease, 2nd or 3rd degree AV block, cardiac pacemaker implantation, or other cases where β-blocker cannot be used under the judgment of the clinician) * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment). * History of atrial fibrillation * Pregnancy or breast feeding

Primary outcome measure(s)

  • Major adverse cardiac events — 2.5 years after last patient enrollment
    a composite of all-cause death, myocardial infarction, hospitalization for heart failure

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul South Korea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04769362 on ClinicalTrials.gov ↗ ← All trials in South Korea